生物药物治疗的松性皮肤病:一个系统性审查
Bowen Tan1, Meng Chen1, Xinru Hu1
1Department of Dermatovenereology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, People's Republic of China.
Clinical, cosmetic and investigational dermatology
|December 22, 2025
概括
与瘤坏死因子-α (TNF-α) 抑制剂相比,介质素 (IL) 抑制剂显示出较快的缓解时间,用于皮肤质性瘤. 虽然这两种生物药物类别的疗效相似,但IL抑制剂比某些TNF-α药物 (如因弗利西马布) 提供更快的结果和更少的副作用.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 皮肤炎 (Pyoderma gangrenosum,简称PG) 是一种罕见的性皮肤病,治疗选择有限.
- 传统疗法如葡萄糖皮质激素和免疫抑制剂具有显著的副作用和可变的疗效.
- 包括TNF-α和IL抑制剂在内的生物药物正在成为PG管理的有效和更安全的替代品.
研究的目的:
- 系统地审查和比较TNF-α抑制剂和IL抑制剂的治疗结果,在患有松性皮肤炎的患者中.
- 评估在PG治疗中使用的不同生物药物的疗效和安全性.
主要方法:
- 在PubMed上进行了全面的文献搜索,确定了107项相关研究.
- 系统审查遵循了系统审查和元分析 (PRISMA) 准则的首选报告项目.
- 分析了139名接受TNF-α抑制剂 (n=92) 或IL抑制剂 (n=47) 治疗的患者的数据.
主要成果:
- 对于TNF-α抑制剂 (88.0%) 和IL抑制剂 (93.6%) 的总疗效率都很高,没有统计学上显著的差异 (p>0.05).
- 与TNF-α抑制剂相比,IL抑制剂在实现部分或完全缓解的时间较短.
- 像Infliximab (一种TNF-α抑制剂) 这样的特定药物与更高的不良事件数量和多样性有关.
结论:
- 两种TNF-α和IL抑制剂都是有效的生物治疗 pyoderma gangrenosum.
- IL抑制剂由于更快的缓解时间和潜在的更好的安全性,因此具有潜在的优势.
- 由于其报告的副作用范围更广泛,因fliximab需要谨慎使用.
相关概念视频
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
285
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
285
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
445
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
445
02:49Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K